Eyes on GLP-1: Impact on Ocular Health

ADA Member Exclusive Webinar

Join American Diabetes Association® (ADA) professional members for Eyes on GLP‑1: Impact on Ocular Health, a focused, one‑hour live discussion exploring how GLP‑1 receptor agonists may influence ocular health. This session will review current evidence linking GLP‑1 therapy to various ocular outcomes and outline key monitoring and counseling considerations for patients using these therapies, concluding with practical insights and an interactive Q&A.

Overview

Join American Diabetes Association® (ADA) professional members for Eyes on GLP‑1: Impact on Ocular Health, a focused, one‑hour live discussion exploring how GLP‑1 receptor agonists may influence ocular health. This session will review current evidence linking GLP‑1 therapy to various ocular outcomes and outline key monitoring and counseling considerations for patients using these therapies, concluding with practical insights and an interactive Q&A.

Learning Objectives

Describe how GLP-1 receptor agonists may affect ocular health.
Review evidence linking GLP-1 therapy to ocular outcomes.
Identify monitoring and counseling considerations for patients on GLP-1 therapy.

Speaker

Brian VanderBeek, MD, MPH, MSCE
Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania

Moderator

Andrew J. Barkmeier, M.D.
Ophthalmologist, Mayo Clinic

Summary

Availability:

Registration Required

Expires on Dec 31, 2026

Location:

Online Meeting

Date / Time:

Mar 25, 2026 12:00 PM - 1:00 PM ET

Cost:

FREE

Credit Offered:

No Credit Offered

Create Account